首页 / 院系成果 / 成果详情页

TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma 期刊论文

编号：

7060b159-a2bd-4b18-8bc6-0cfaa08382f6
作者：

Xiao, Wenjing^[1] Du, Nan^[2] Huang, Taoyuan^[3] Guo, Jinan^[4] Mo, Xingkui^[5] Yuan, Tao^[5] Chen, Yong^[6] Ye, Ting^[7] Xu, Chunwei^[8] Wang, Wenxian^[9] Wang, Guoqiang^[9] Cai, Shangli^[10] Chen, Jing^[7]
语种：

英文
期刊：

EBIOMEDICINE ISSN：2352-3964 2018 年 32 卷 (119 - 124) ; JUN
收录：
关键词：

Anti-CTLA-4 TP53 Melanoma Biomarker Tumor mutational
摘要：

TP53 has been proved to be associatedwith cytotoxic T-cell induced apoptosis, however, the association between TP53 and the benefit of immunotherapy in melanoma has not been studied. In the present study, we examined the relationship between TP53 mutation and response to CTLA-4 blockade in metastatic melanoma by analyzing the data from one public cohort consisting of 110 patients with metastatic melanoma. The sequencing, mRNA and survival data of 368 patients with skin melanoma from The Cancer Genome Atlas (TCGA) was used to explore the underlying mechanism. TP53 mutation was associated with significant poorer progression-free survival (HR, 2.25; 95% CI, 1.15-4.37; P = 0.014), poorer overall survival (HR, 2.05; 95% CI, 1.02-4.13; P = 0.040) and trend of poorer response (OR, 0.20; 95% CI, 0.02-1.62; P = 0.131). The correlations were significant in multivariate analysis including lactate dehydrogenase, tumor mutational burden and tumor stage (P < 0.05). In TCGA, no association was observed between TP53 mutation and survival (P = 0.55). The mRNA expression of FAS was lower in patientswith TP53 mutation than TP53wild-type. Our findings suggest that TP53mutation is a potential negative predictor of metastatic melanoma treated with CTLA-4 blockade. (C) 2018 The Authors. Published by Elsevier B.V.
推荐引用方式
GB/T 7714：

Xiao Wenjing,Du Nan,Huang Taoyuan, et al. TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma [J].EBIOMEDICINE,2018,32:119-124.
APA：

Xiao Wenjing,Du Nan,Huang Taoyuan,Guo Jinan,&Chen Jing.(2018).TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma .EBIOMEDICINE,32:119-124.
MLA：

Xiao Wenjing, et al. "TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma" .EBIOMEDICINE 32(2018):119-124.

浏览次数：9  下载次数：0

分享到：

浏览次数：9

下载次数：0

打印次数：0